568 related articles for article (PubMed ID: 33031846)
21. Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma.
Lee SU; Kim TH
Clin Mol Hepatol; 2023 Oct; 29(4):958-968. PubMed ID: 37822213
[TBL] [Abstract][Full Text] [Related]
22. Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study.
Choi JW; Lee JM; Lee DH; Yoon JH; Kim YJ; Lee JH; Yu SJ; Cho EJ
PLoS One; 2020; 15(9):e0239733. PubMed ID: 32986758
[TBL] [Abstract][Full Text] [Related]
23. Minimally invasive surgery versus radiofrequency ablation for single subcapsular hepatocellular carcinoma ≤ 2 cm with compensated liver cirrhosis.
Lin CH; Ho CM; Wu CH; Liang PC; Wu YM; Hu RH; Lee PH; Ho MC
Surg Endosc; 2020 Dec; 34(12):5566-5573. PubMed ID: 31993821
[TBL] [Abstract][Full Text] [Related]
24. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis.
Liu W; Zheng Y; He W; Zou R; Qiu J; Shen J; Yang Z; Zhang Y; Wang C; Wang Y; Zuo D; Li B; Yuan Y
Aliment Pharmacol Ther; 2018 Sep; 48(6):671-681. PubMed ID: 30063081
[TBL] [Abstract][Full Text] [Related]
25. Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis.
Kim DY; Park JW; Kim TH; Kim BH; Moon SH; Kim SS; Woo SM; Koh YH; Lee WJ; Kim CM
Radiother Oncol; 2017 Jan; 122(1):122-129. PubMed ID: 28034460
[TBL] [Abstract][Full Text] [Related]
26. Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma.
Iizumi T; Okumura T; Sekino Y; Takahashi H; Tsai YL; Takizawa D; Ishida T; Hiroshima Y; Nakamura M; Shimizu S; Saito T; Numajiri H; Mizumoto M; Nakai K; Sakurai H
J Radiat Res; 2021 Jul; 62(4):682-687. PubMed ID: 34036362
[TBL] [Abstract][Full Text] [Related]
27. Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.
Seidensticker M; Öcal O; Schütte K; Malfertheiner P; Berg T; Loewe C; Klümpen HJ; van Delden O; Ümütlü MR; Ben Khaled N; de Toni EN; Seidensticker R; Aghdassi A; Tran A; Bronowicki JP; Peynircioglu B; Sangro B; Pech M; Ricke J
JHEP Rep; 2023 May; 5(5):100699. PubMed ID: 36968218
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy of no-touch radiofrequency ablation in the treatment of single small hepatocellular carcinoma: A single center long-term follow-up study.
Wu G; Li J; Li C; Ou X; Feng K; Xia F; Chen Z; Zhang L; Ma K
Cancer Med; 2023 Mar; 12(6):6571-6582. PubMed ID: 36444873
[TBL] [Abstract][Full Text] [Related]
29. [Clinical application of ultrasound-guided radiofrequency ablation for primary hepatocellular carcinoma near the liver surface].
Wu J; Lin S; Wu W; Yan K; Dai Q; Chen M
Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):933-7. PubMed ID: 26887624
[TBL] [Abstract][Full Text] [Related]
30. Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial.
Chen K; Chen G; Wang H; Li H; Xiao J; Duan X; He J; He K; Xiang G
J Hepatol; 2014 Dec; 61(6):1304-11. PubMed ID: 25064436
[TBL] [Abstract][Full Text] [Related]
31. Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis.
Yang Y; Yu H; Tan X; You Y; Liu F; Zhao T; Qi J; Li J; Feng Y; Zhu Q
Int J Hyperthermia; 2021; 38(1):875-886. PubMed ID: 34078221
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis.
Wang X; Liu G; Chen S; Bi H; Xia F; Feng K; Ma K; Ni B
Int J Hyperthermia; 2021 Oct; 38(1):1519-1528. PubMed ID: 34702122
[TBL] [Abstract][Full Text] [Related]
33. Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis.
An C; Li WZ; Huang ZM; Yu XL; Han YZ; Liu FY; Wu SS; Yu J; Liang P; Huang J
Eur Radiol; 2021 Jul; 31(7):4764-4773. PubMed ID: 33399908
[TBL] [Abstract][Full Text] [Related]
34. Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: A randomized, double-blinded, dummy-controlled clinical trial in a single center.
Yang W; Lee JC; Chen MH; Zhang ZY; Bai XM; Yin SS; Cao K; Wang S; Wu W; Yan K
J Cancer Res Ther; 2019; 15(4):773-783. PubMed ID: 31436231
[TBL] [Abstract][Full Text] [Related]
35. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial.
Di Costanzo GG; Tortora R; D'Adamo G; De Luca M; Lampasi F; Addario L; Galeota Lanza A; Picciotto FP; Tartaglione MT; Cordone G; Imparato M; Mattera S; Pacella CM
J Gastroenterol Hepatol; 2015 Mar; 30(3):559-65. PubMed ID: 25251043
[TBL] [Abstract][Full Text] [Related]
36. A Phase 2 Study of Image-Guided Proton Therapy for Operable or Ablation-Treatable Primary Hepatocellular Carcinoma.
Iwata H; Ogino H; Hattori Y; Nakajima K; Nomura K; Hashimoto S; Hayashi K; Toshito T; Sasaki S; Mizoe JE; Shibamoto Y
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):117-126. PubMed ID: 33798564
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
Doyle A; Gorgen A; Muaddi H; Aravinthan AD; Issachar A; Mironov O; Zhang W; Kachura J; Beecroft R; Cleary SP; Ghanekar A; Greig PD; McGilvray ID; Selzner M; Cattral MS; Grant DR; Lilly LB; Selzner N; Renner EL; Sherman M; Sapisochin G
J Hepatol; 2019 May; 70(5):866-873. PubMed ID: 30615906
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
39. Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC.
Hocquelet A; Aubé C; Rode A; Cartier V; Sutter O; Manichon AF; Boursier J; N'kontchou G; Merle P; Blanc JF; Trillaud H; Seror O
J Hepatol; 2017 Jan; 66(1):67-74. PubMed ID: 27422750
[TBL] [Abstract][Full Text] [Related]
40. Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy.
Hsieh CE; Venkatesulu BP; Lee CH; Hung SP; Wong PF; Aithala SP; Kim BK; Rao A; Tung-Chieh Chang J; Tsang NM; Wang CC; Lee CC; Lin CC; Tseng JH; Chou WC; Wang YC; Krishnan S; Hong JH
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):73-86. PubMed ID: 30797890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
